Several circulating miRNAs related to hyperlipidemia and atherosclerotic cardiovascular diseases

Abstract

Background In recent years, an increasing number of studies have proved that circulating miRNAs could be used for the early diagnosis of cardiovascular diseases and even play vital roles in the evaluation of therapeutic effects or prognosis. This study was conducted to examine the correlation between serum microRNAs and hyperlipidemia to provide a theoretical basis for the early screening and intervention of atherosclerotic cardiovascular diseases (ASCVD). Methods The serum samples and clinical data of 122 patients with hyperlipidemia and 168 healthy subjects were collected. Related clinical information was statistically analyzed for the two groups. Expression of circulating miRNAs was detected by miRNA microarray analysis and further verified by reverse transcription-quantitative PCR (RT-qPCR). Results Statistical analysis of clinical information revealed a significant difference in the incidence of ASCVD between the two groups. The MiRNA microarray analysis ( n = 10) showed 22 miRNAs with significantly different expression, among which 12 showed upregulation, and the others showed downregulation. Those possessing obvious differences and stable expression in the miRNA microarray, including miRNA-191-3p, miRNA-933, and miRNA-425-3p, were chosen for further investigation using RT-qPCR. The results demonstrated that several miRNAs were related to lipid metabolism disorders, especially miRNA-933. The area under the curve (AUC) of miRNA-933 in distinguishing the hyperlipidemia and ASCVD patients was 0.739 (95% CI, 0.682–0.795; P < 0.01) and 0.703 (95% CI, 0.643–0.763, P < 0.01), respectively. Conclusions In conclusion, miRNA-191-3p, miRNA-933, and miRNA-425-3p may be depressed in the peripheral circulation of patients with lipid metabolism disorders (mainly LDL). Circulating miRNA-933 could be a feasible predictor for ASCVD at the early stage. Electronic supplementary material The online version of this article (10.1186/s12944-019-1046-z) contains supplementary material, which is available to authorized users.

The role of miR-320 in glucose and lipid metabolism disorder-associated diseases

“…Initial miRNA-associated studies were mainly focused on cancer development, cardiovascular diseases, and metabolic diseases. It was found that the expression profile of miRNAs was changed in plasma and tissue samples under disease conditions such as cancer [11], hyperlipidemia [12], hyperglycemia [13], endothelial cell dysfunction [14] and diabetes [15]. We also identified the altered expression of circulating miRNAs in patients with coronary heart disease (CHD), compared with healthy…”

Association between MicroRNA-4669 Polymorphism and Ischemic Stroke in a Korean Population

“…NIHSS score was higher in IS patients with the A/A genotype of rs79402775 than with the G/G or G/A genotypes. A recent study showed that miRNA-933 was significantly decreased in the peripheral circulation of patients with hyperlipidemia and with atherosclerotic cardiovascular diseases (ASCVD) [31]. Thus, authors suggested circulating miRNA-933 as a feasible predictor for ASCVD at the early stage [31].…”

“…A recent study showed that miRNA-933 was significantly decreased in the peripheral circulation of patients with hyperlipidemia and with atherosclerotic cardiovascular diseases (ASCVD) [31]. Thus, authors suggested circulating miRNA-933 as a feasible predictor for ASCVD at the early stage [31]. On the contrary, other study reported that 27-hydroxycholesterol, a cholesterol metabolite, increased the level of miRNA-933 in microvascular endothelial cells along with the elevation of TNF- α and IL-6 [32].…”

Advancements in microRNA research in dyslipidemia

“…表达升高, 并与血浆TC水平呈正相关; miR-122及miR-34a表达升高, 并与血TG及VLDL-C水平正相关. Xu等 人 [16] 分析了高脂血症患者和健康受试者循环miRNA 的表达, 发现miR-933可能与高LDL-C有关. Guo等 人 [38] 发现, 高脂血症患者血清中miR-587的表达较健 康对照中的降低, 并与血TC负相关.…”